Patents by Inventor Cara Weismann

Cara Weismann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods and compositions for treating GM1 gangliosidosis
    Patent number: 12648978
    Abstract: Aspects of the invention relate to recombinant adeno-associated viruses (rAAVs). In some aspects, the rAAVs comprise artificial genetic regulatory elements that modulate transgene expression. In some aspects, the disclosure relates to the treatment of lysosomal storage disorders.
    Type: Grant
    Filed: May 28, 2021
    Date of Patent: June 9, 2026
    Assignee: University of Massachusetts
    Inventors: Miguel Sena-Esteves, Cara Weismann, Diane Golebiowski, Lorelei Stoica
  • Modulation of AAV Vector Transgene Expression
    Publication number: 20210393714
    Abstract: Aspects of the invention relate to recombinant adeno-associated viruses (rAAVs). In some aspects, the rAAVs comprise artificial genetic regulatory elements that modulate transgene expression. In some aspects, the disclosure relates to the treatment of lysosomal storage disorders.
    Type: Application
    Filed: May 28, 2021
    Publication date: December 23, 2021
    Inventors: Miguel Sena-Esteves, Cara Weismann, Diane Golebiowski, Lorelei Stoica
  • Modulation of AAV vector transgene expression
    Patent number: 11020443
    Abstract: Aspects of the invention relate to recombinant adeno-associated viruses (rAAVs). In some aspects, the rAAVs comprise artificial genetic regulatory elements that modulate transgene expression. In some aspects, the disclosure relates to the treatment of lysosomal storage disorders.
    Type: Grant
    Filed: April 20, 2016
    Date of Patent: June 1, 2021
    Assignee: University of Massachusetts
    Inventors: Miguel Sena Esteves, Cara Weismann, Diane Golebiowski, Lorelei Stoica
  • MODULATION OF AAV VECTOR TRANSGENE EXPRESSION
    Publication number: 20180311290
    Abstract: Aspects of the invention relate to recombinant adeno-associated viruses (rAAVs). In some aspects, the rAAVs comprise artificial genetic regulatory elements that modulate transgene expression. In some aspects, the disclosure relates to the treatment of lysosomal storage disorders.
    Type: Application
    Filed: April 20, 2016
    Publication date: November 1, 2018
    Applicant: University of Massachusetts
    Inventors: Miguel Sena-Esteves, Cara Weismann, Diane Golebiowski, Lorelei Stoica